Abstract
Vedolizumab is a monoclonal IgG1 antibody, which has been approved to use in clinical practice for ulcerative colitis patients in Europan Union a few months ago. There is a big expectation on availability of vedolizumab at the market in Czech Republic in these year.
The clinical research named GEMINI I proved that vedolizumab is a very effective drug in patients with moderate to severe ulcerative colitis. The significant advantages of vedolizumab therapy is a high efficacy in those patients who failed to anti-TNFα therapy, sustained response due to maintenance therapy with arising effect over time, a minimal drug's immunogenicity and highly safety drug's profile, which is caused by a high selectivity for gastrointestinal tract.
There are some disadvantages or uncertainty which include slow antiinflammatory therapeutic response, restricted effect on extraintestinal manifestations.